To build on its existing remote clinical trial participant data collection products, ERT has launched a cardiac safety platform that allows electrocardiogram (ECG) to evaluate the safety of new drugs remotely from a patient’s home.

This prevents the disruption of ongoing trials during the Covid-19 pandemic when many countries in the world have implemented lockdowns of its citizens.

ERT chief medical officer and vice-president of Cardiology Robert Kleiman said: “With ERT’s At-home ECG solution, clinical researchers can continue assessing the cardiovascular risk of new medical treatments, even while patients are adhering to local and nationally mandated quarantines.”

This remote approach will also support vaccine and drug development against the novel coronavirus. ERT cardiac safety executive vice-president Ellen Street commented: “With so many new compounds being developed and fast-tracked through FDA for the prevention and treatment of COVID-19, it’s more important than ever for researchers to have access to the tools that meet their development timelines while keeping patient safety at the forefront.

“We’re pleased to apply our expertise, proven infrastructure, and flexibility to help researchers meet their development objectives; especially now during the uncertain times the industry is facing.”